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ABSTRACT 
 
Central nervous system (CNS) deficiencies of the monoamine neurotransmitters 
dopamine and serotonin have been implicated in the pathophysiology of 
neuropsychiatric dysfunction in human phenylketonuria (PKU). In this study, we 
confirmed the occurrence of brain dopamine and serotonin deficiencies in association 
with severe behavioral alterations and cognitive impairments in hyperphenylalaninemic 
C57BL/6-Pahenu2/enu2 mice, a model of human PKU. Phenylalanine-reducing treatments, 
including either dietary phenylalanine restriction or liver-directed gene therapy, initiated 
during adulthood were associated with increased brain monoamine content along with 
improvements in nesting behavior but without a change in the severe cognitive deficits 
exhibited by these mice. At euthanasia, there was in Pahenu2/enu2 brain a significant 
reduction in the protein abundance and maximally stimulated activities of tyrosine 
hydroxylase (TH) and tryptophan hydroxylase 2 (TPH2), the rate limiting enzymes 
catalyzing neuronal dopamine and serotonin synthesis respectively, in comparison to 
levels seen in wild type brain. Phenylalanine-reducing treatments initiated during 
adulthood did not affect brain TH or TPH2 content or maximal activity. Despite this 
apparent fixed deficit in striatal TH and TPH2 activities, initiation of phenylalanine-
reducing treatments yielded substantial correction of brain monoamine neurotransmitter 
content, suggesting that phenylalanine-mediated competitive inhibition of already 
constitutively reduced TH and TPH2 activities is the primary cause of brain monoamine 
deficiency in Pahenu2 mouse brain. We propose that CNS monoamine deficiency may be 
the cause of the partially reversible adverse behavioral effects associated with chronic 
HPA in Pahenu2 mice, but that phenylalanine-reducing treatments initiated during 
adulthood are unable to correct the neuropathology and attendant cognitive deficits that 
develop during juvenile life in late-treated Pahenu2/enu2 mice. 
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1. INTRODUCTION 
Phenylketonuria (PKU), due to recessively inherited phenylalanine hydroxylase (PAH) 
deficiency (Figure 1) (OMIM # 261600), is among the most common inborn errors of 
metabolism in humans. Hyperphenylalaninemia (HPA), if left untreated, is associated 
with severely impaired brain growth and development yielding profound cognitive 
disability. Early disease detection through neonatal screening and initiation of dietary 
phenylalanine (Phe) restriction within the first weeks of life prevents the major 
manifestations of the disease (Azen et al. 1991). However, chronically elevated blood 
Phe due to loss of dietary control in adolescents and adults with early-treated PKU is 
frequently associated with disturbed executive functioning (VanZutphen et al. 2007; 
Christ et al. 2010), psychiatric symptoms (Bilder et al. 2013), and in extreme cases can 
be associated with adult onset white matter degeneration, ataxia and seizures 
(Thompson et al. 1990). The proximate pathologic mechanisms that mediate the 
neurobehavioral effects of HPA are incompletely understood, but abundant evidence 
implicates dysfunction of the dopaminergic and serotonergic neuronal systems as having 
major roles in the symptoms of anxiety and impaired executive functioning associated 
with HPA (Christ et al. 2010; de Groot et al. 2010; Feillet et al. 2010). Here, we further 
investigate the relationships between HPA, monoamine neurotransmitter deficiency, 
behavior, and cognition in a murine model of human PKU. 
 
The Pahenu2 mouse, a model of human PKU (McDonald et al. 1990), harbors a missense 
mutation in the seventh exon of the Pah gene (McDonald and Charlton 1997) that yields 
complete PAH deficiency in homozygous mice. Untreated Pahenu2/enu2 mice exhibit HPA, 
growth failure (McDonald 2000), hypopigmentation, maternal effects upon fetal 
development (McDonald et al. 1997) and cognitive deficits including impaired memory 
(Zagreda et al. 1999; Cerreto et al. 2012; Bruinenberg et al. 2016) and spatial 
recognition (Cabib et al. 2003). Significant CNS dopamine and serotonin deficiencies 
have been measured in hyperphenylalaninemic Pahenu2/enu2 mice (Puglisi-Allegra et al. 
2000; Pascucci et al. 2002; Pascucci et al. 2008; Harding et al. 2014; Winn et al. 2016), 
and these deficiencies have been implicated in the pathogenesis of the memory deficits 
exhibited by these animals (Zagreda et al. 1999; Bruinenberg et al. 2016). The central 
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elements of monoamine neurotransmitter synthesis and the turnover of these 
neurotransmitters are depicted in Figure 1 and inspection of the pathway leads to the 
two hypotheses proposed to explain monoamine neurotransmitter deficiency in PKU. 
According to the first hypothesis, HPA competitively reduces transport of L-tyrosine (Tyr) 
and L-tryptophan (Trp), the substrates for dopamine and serotonin synthesis 
respectively, across the blood-brain barrier and into the brain (Pietz et al. 1999). 
According to the second hypothesis, elevated brain Phe competitively inhibits the 
activities of tyrosine hydroxylase (TH) and tryptophan hydroxylase 2 (TPH2), the 
enzymes catalyzing the rate-limiting steps in neuronal dopamine and serotonin synthesis 
respectively (Ogawa and Ichinose 2006). Here, in order to more fully understand the 
pathophysiology of the PKU phenotype, we examined the behavioral and cognitive 
phenotypes of hyperphenylalaninemic C57BL/6-Pahenu2/enu2 mice in comparison to their 
wild type and Pahenu2 heterozygous littermates. In addition, we report the effects of two 
different Phe-reducing treatments, namely dietary Phe restriction or liver-directed gene 
therapy with a PAH-expressing recombinant adeno-associated virus serotype 8 
(rAAV2/8) vector (Figure 1), upon blood and brain amino acid and brain monoamine 
neurotransmitter contents and upon the behavioral and cognitive phenotypes of 
Pahenu2/enu2 mice. Our hypotheses were that correction of serum and consequently brain 
phenylalanine concentrations following administration of either dietary phenylalanine 
restriction or liver gene therapy to restore liver PAH activity would lead to functionally 
increased brain TH and TPH2 activity and correction of brain dopamine and serotonin 
content in hyperphenylalaninemic Pahenu2/enu2 mice. Furthermore, we proposed that 
correction of brain monoamine neurotransmitter content would be associated with 
improvement in the behavioral and cognitive phenotypes of hyperphenylalaninemic 
Pahenu2/enu2 mice. 
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Figure 1. Phenylketonuria, effects of hyperphenylalaninemia upon brain 
monoamine neurotransmitter metabolism, and phenylalanine-lowering treatments 
applied in this work.  
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Pahenu2/enu2 mice lack phenylalanine hydroxylase (PAH) activity in liver and cannot 
convert L-phenylalanine (Phe) to L-tyrosine (Tyr).  Tyr and L-tryptophan (Trp) are the 
substrates for dopamine (DA) and serotonin synthesis respectively in brain. Both amino 
acids cross the blood brain barrier and enter neurons via diffusion facilitated by the LAT1 
neutral amino acid transporter in competition with Phe and other large neutral amino 
acids. Tyr is converted to L-DOPA by tyrosine hydroxylase (TH), the rate-limiting 
enzyme in DA synthesis. TH activity is stimulated by Tyr, but inhibited through Phe-
mediated competition, DA or L-DOPA-mediated feedback inhibition, and via a DA-
activated, G-protein coupled, synthesis-modulating autoreceptor. TH activity is also 
regulated through reversible phosphorylation triggered by a variety of stimuli (not 
shown). DA is synthesized from L-DOPA by aromatic amino acid decarboxylase 
(AADC), taken up into secretory vesicles via a monoamine specific transporter (VMAT2) 
and secreted into the synapse following Ca+2 influx in response to a nerve stimulus. 
Neurotransmission terminates through DA reuptake via a specific transporter (DAT) or 
through degradation of DA to homovanillic acid (HVA), hence brain HVA content 
can be taken as a measure of DA turnover. Extracellular DA can also act via another G 
protein-coupled autoreceptor to suppress further synaptic DA release. Analogous 
mechanisms regulate the synthesis and secretion of serotonin from Trp followed by 
degradation to 5-hydroxyindoleacetic acid (5-HIAA). The present work has been based 
upon the hypothesis that correction of serum and consequently brain phenylalanine 
concentrations following administration of either DIETARY PHENYLALANINE 
RESTRICTION or AAV8-mediated LIVER GENE THERAPY to restore liver PAH activity 
would lead to functionally increased brain TH and TPH2 activity and correction of brain 
dopamine and serotonin content in hyperphenylalaninemic Pahenu2/enu2 mice. 
Furthermore, we proposed that correction of brain monoamine neurotransmitter content 
would be associated with improvement in the behavioral and cognitive phenotypes of 
hyperphenylalaninemic Pahenu2/enu2 mice. 
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2. MATERIALS AND METHODS 
2.1 Animal husbandry. Animal care and experimentation were performed in accordance 
with the guidelines of the Dept. of Comparative Medicine, Oregon Health & Science 
University and the National Institutes of Health Guide for the Care and Use of Laboratory 
animals. C57Bl/6-Pahenu2/enu2 mice (Pah-/-), derived from the original BTBR-Pahenu2/enu2 
strain (McDonald et al. 1990), are homozygous for a missense mutation in exon 7 of the 
murine Pah gene, are completely deficient in liver PAH activity, are consequently 
hyperphenylalaninemic on an unrestricted diet, and are a representative animal model of 
human PKU. Genotyping for the presence of the Pahenu2 mutation was performed by a 
PCR-based analysis (Harding et al. 1998) or a Taqman quantitative PCR assay. Control 
animals including wild type C57Bl/6 mice (Pah+/+) and Pahenu2/+ heterozygotes, which 
were co-reared littermates of Pah-/- mice resulting from Pahenu2/+ X Pahenu2/+ breedings in 
our mouse colony. For the first month after weaning until the onset of the experimental 
trial at two months age, all mice were fed tap water and standard mouse chow (Lab Diet 
Picolab Rodent diet 20, PMI Nutrition International, St. Louis, MO) ad libitum providing 
approximately 24% protein and 1.04% L-phenylalanine by weight. Given that adult mice 
consume approximately 5 g chow per day, daily L-phenylalanine intake is estimated to 
be approximately 50 mg per day. The animals were housed under a standard 12 hours 
on, 12 hours off light cycle. All surgical procedures were carried out with inhaled 
isoflurane general anesthesia to minimize pain and discomfort. 
 
2.2 Dietary phenylalanine restriction trial. Eighteen Pah-/- mice (9 males and 9 females) 
were switched from standard mouse chow to a phenylalanine (Phe)-restricted diet at 8 
weeks age. The animals consumed a Phe free mouse chow (Harlan Teklad TD.01642); 
their drinking water was supplemented with L-phenylalanine (Sigma-Aldrich), 50 mg/100 
ml (0.05%) to prevent Phe deficiency. Given a typical drinking water intake of 3 ml per 
day, the estimated daily Phe intake on this regimen was 0.15 mg per day, and this 
amount of Phe supplementation was known from previous work to maintain blood 
phenylalanine in Pah-/- mice to within or slightly above the normal range of blood 
phenylalanine in wild type mice. This diet was continued for eight weeks and then the 
animals underwent detailed behavioral and cognitive testing as described below. The 
low Phe diet was continued through the testing period until euthanasia at 18-20 weeks 
age for a total exposure of 10-12 weeks dietary Phe restriction. As controls, fourteen 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 9 
additional Pah-/- mice (6 males and 8 female) and eighteen Pah+/+ or Pah+/- mice, 
littermates to the low phenylalanine diet group, continued to receive standard mouse 
chow (23.9% protein and 1.05% Phe by weight)  and drinking water through the same 
period and were also assessed using the same behavioral and cognition testing 
protocol. 
 
2.3 Liver-directed adeno-associated virus vector-mediated gene therapy. Eleven Pah-/- 
mice (4 males and 7 females) were treated with PAH-expressing recombinant adeno-
associated virus serotype 8 (rAAV2/8 vector) by portal vein injection at 8 weeks age. 
This rAAV2/8 vector harbors the murine Pah cDNA under the transcriptional control of a 
strong liver specific promoter (LSP) and has been previously shown by our laboratory to 
correct blood Phe in treated Pah-/- mice (Harding et al. 2006). The rAAV2/8 vector was 
prepared by the OHSU Viral Vector Core using triple transfection of the required 
recombinant plasmids into cultured 293K cells and purification by cesium chloride 
density centrifugation using standard methods. The titer of viral genomes in the 
preparation was determined by quantitative PCR. Each animal received 2.5 X 1011 
rAAV2/8 vector genomes (vg) in 100 µl sterile saline by open laparotomy and direct 
injection into the portal vein. Treated mice continued to receive standard mouse chow 
and drinking water ad libitum for eight weeks following rAAV2/8 injection before 
undergoing behavioral and cognitive assessment at 16 weeks age. The mice were 
euthanized at 18-20 weeks age for tissue harvest. Ten Pah+/+ and eleven additional 
Pah-/- mice, littermates of the rAAV2/8 treated group, did not receive any AAV 
treatment, continued on standard mouse chow and drinking water, and served as 
contemporaneous controls for behavioral, cognitive, and biochemical analyses. 
 
2.4 Behavioral and cognitive testing. All mice were tested in the following behavioral and 
cognitive tests in the following order: open field, rotorod, and nest building (week 1), 
water maze (week 2), passive avoidance and contextual and cued fear conditioning 
(week 3). The open field and water maze tests are described below. The rotorod, 
contextual and cued fear conditioning were performed as previously reported (Olsen et 
al. 2013). The passive avoidance test was performed as described (Benice and Raber 
2009). The referenced methods are not further described here because we found no 
effects of either HPA or treatment upon these measures. 
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2.5 Open field: Mice were placed for ten minutes in a 40.64 cm X 40.64 cm brightly lit 
open arena. The movement and location of the mice was recorded with Noldus 
Ethovision video tracking (Wageningen, The Netherlands) and was used to assess 
exploratory behavior and measures of anxiety. The center zone (20.32 x 20.34 cm) and 
peripheral zone (remaining part of the open field) were also analyzed separately to 
assess measurements of anxiety. More anxious mice in the open-field spend less time in 
the more anxiety-provoking center area (Choleris et al. 2001). 
 
2.6 Nest building: Nest building was analyzed as described (Johnson et al. 2015). 
Briefly, animals were singly housed and provided with two cotton squares to build nests. 
48 hours after being housed, photos were taken of the nests built. Two researchers 
blinded to treatment then rated the complexity of the nest on a scale from 1 to 5, where 1 
indicates that the mouse has not torn the cotton squares apart at all, and 5 indicates a 
finished, highly complex nest. The scores from the two researchers were averaged for 
analysis.  
 
2.7 Water maze: Ability to navigate to a visible platform was evaluated using the water 
maze and Ethovision video tracking software. The maze (circular tub, 122 cm diameter) 
contained a platform marked by a beacon. The location of the platform was changed 
between sessions. There were a total of five sessions. Each session consisted of two 
trials. Each test day consisted of 2 sessions, one in the morning and one in the 
afternoon. Each trial was up to 60 seconds with a 10-15 minute inter-trial interval. If the 
mouse did not find the platform in 60 seconds then it was led to the platform by the 
experimenter and allowed to remain there for 3 seconds before being removed from the 
maze. Mice were placed in the water maze facing the wall of the pool at nine different 
drop locations around the pool. The drop location was alternated for each trial. Time to 
reach the platform (latency), cumulative distance to the platform, and swim speeds were 
analyzed. As the PAH-/- mice showed extremely poor ability to locate the visible 
platform, no training sessions with the platform hidden were administered following the 
visible platform training sessions. 
 
2.8 Euthanasia and tissue harvest. Animals were sedated using inhaled isoflurane 
anesthesia. Whole blood was collected by cardiac puncture, allowed to clot in an 
Eppendorf tube, and serum was separated by centrifugation. The mice were then 
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euthanized by exsanguination and perfused with 20 ml normal saline via the left cardiac 
ventricle to clear blood from the cerebral circulation. Following decapitation, whole brain 
was rapidly excised from the cranium, split sagitally, and immediately submerged in 
liquid nitrogen. Half brains and serum samples were stored at -80°C until processing for 
amino acid or neurotransmitter analysis. 
 
2.9 Amino acid analysis. Amino acid concentrations in sera or brain tissue were 
measured by pre-column derivitization with 6-aminoquinolyl-N-hydroxysuccinimidyl 
carbamate (AQC, Waters AccQ Tagderivitization system) and separation by ultra high 
performance liquid chromatography and UV absorbance detection (Waters Acquity 
UPLC, Milford, MA) using the Waters Masstrak Amino Acid Analysis method. Serum 
samples were de-proteinized by adding an equal volume of 10% sulfosalicylic acid 
containing the non-physiological amino acid norvaline (250 µM) as an internal recovery 
standard. For analysis of amino acid concentrations in brain, half-brains were 
mechanically homogenized in 5 volumes/weight 10% trichloroacetic acid containing 
norvaline (150 µM) and processed as previously described (Winn et al. 2016). Serum 
amino acid concentrations were reported as µM and corrected for dilution to reflect the 
actual concentrations in serum. The measured amino acid concentrations in the brain 
homogenates were corrected for the tissue wet weight and reported as nmol/gm wet 
brain weight. 
 
2.10 Brain monoamine neurotransmitter analysis. Mouse half-brains were mechanically 
homogenized in ice-cold homogenizing buffer (50 mM Tris-HCl, pH 7.5, 0.1 M KCl, 1 mM 
EDTA, 1 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride, 1 µM leupeptin, and 1 
µM pepstatin), 4 µl/mg tissue and further processed according to a previously published 
method (Elzaouk et al. 2003). Monoamine neurotransmitter concentrations (L-DOPA, 
dopamine, HVA, 5-HTP, serotonin, and 5-HIAA) were measured in brain tissue by HPLC 
and electrochemical detection (Blau et al. 1999). Measured brain homogenate 
monoamine neurotransmitter concentrations were corrected for the protein content of the 
homogenate and expressed as pmol/mg protein. 
 
2.11 Measurement of brain TH and TPH abundance and activities. Immunodetection of 
TH and TPH protein relative to GAPDH protein and measurement of maximally 
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stimulated TH and TPH activities in mouse half-brain homogenates were carried out 
essentially as previously described (Calvo et al. 2010). 
 
2.12 Brain TH and TPH immunohistology. Select animals from each experimental cohort 
underwent saline-paraformaldehyde perfusion in preparation for brain fixation and 
immunohistology. Under deep isoflurane inhaled anesthesia, mice were perfused with 
0.9% saline via cardiac infusion to clear the cerebral circulation of blood and then were 
perfused with an equal volume of fixative solution (4% paraformaldehyde in phosphate 
buffered saline). Excised whole brains were then fixed for 24 hours in the same fixation 
solution followed by dehydration in 25% buffered sucrose for an additional 24 hours. 15 
micrometer coronal frozen sections were then cut from the regions of the striatum using 
a cryostat and mounted on glass slides. Sections were treated (following blocking) with 
rabbit polyclonal anti-TH antibody (1:200 dilution, EMD Millipore Corp. AB152) and 
incubated for 2 hours at room temperature. After appropriate washes, sections were 
treated with Alexa 488-conjugated goat anti-rabbit IgG secondary antibody (1:150 
dilution, Thermo Scientific, A27034) and incubated for one hour at room temperature. 
After washing, cover slips were mounted with Vectashield mounting medium containing 
DAPI. Images were captured on a Nikon H550L fluorescence microscope. 
 
2.13 Statistical analysis. Biochemical, behavioral, and cognitive, data were analyzed 
using two-way analyses of variance (ANOVA) with either genotype and sex or sex and 
treatment as between-subjects factors. The water maze learning curves were analyzed 
using repeated-measures ANOVA with genotype or treatment as between group 
variables. Inter-group comparisons were performed post analysis using Tukey’s multiple 
comparison tests when appropriate. We considered p < 0.05 as statistically significant. 
Statistical analyses of biochemical data were performed using GraphPad Prism™ 
(version 7, San Diego, CA) software. Statistical analyses of behavioral and cognitive 
data were performed using SPSS software (vs22, Chicago, IL).  
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3. RESULTS  
3.1 Murine HPA is associated with severe CNS serotonin deficiency but minimal 
disturbance of brain dopamine or large neutral amino acid (LNAA) content.  
Five month old adult PAH-deficient C57Bl/6-Pahenu2/enu2 (Pah-/-) mice consuming a 
standard mouse chow (23.9% protein and 1.05% Phe by weight) exhibit severe HPA and 
elevated brain Phe in comparison to either Pah+/+ or Pah+/- littermates (Figure 2 and 
Supplementary Table 1). The mean serum Phe concentration (Figure 2A) in male Pah-/- 
mice (2198 ± 71 µM) was increased more than ten-fold over male Pah+/+ (132 ± 16 µM) 
or Pah+/- mice (98 ± 23 µM). Female Pah-/- mice exhibited even greater blood Phe 
concentration (2654 ± 87 µM) in comparison to female Pah+/+ (111 ± 11 µM) or Pah+/- 
mice (72 ± 7 µM). Two-way ANOVA revealed significant effects of both genotype 
(F(2,47) = 716, p < 0.0001) and sex (F(1,47) = 4.24, p < 0.0451) upon serum 
phenylalanine (Phe). This sex difference in serum Phe of Pahenu2/enu2 mice has been 
noted previously (Hamman et al. 2005; Ding et al. 2008), but to the best of our 
knowledge has not been described in humans with PKU. Brain Phe concentration 
(Figure 2B) was similarly increased in Pah-/- mice (male Pah -/- mice = 713 ± 18 
nmol/gm wet brain weight, female Pah -/- mice = 811 ± 17 nmol/gm) in comparison to 
either Pah+/+ (male = 110 ± 28 nmol/gm, female = 85 ± 15 nmol/gm) or Pah+/- mice 
(male mice = 194 ± 13 nmol/gm, female = 171 ± 14 nmol/gm). A plot of brain 
phenylalanine content vs. serum phenylalanine concentration in all mice (including 
untreated mice of all three genotypes and all Pah-/- mice treated with dietary Phe 
restriction or liver-directed gene therapy described below) demonstrated a tight 
correlation between Phe concentration in blood and brain (r2 = 0.914, p < 0.0001, Figure 
2C).  
 
The LNAA (including Phe, tyrosine, tryptophan, leucine, isoleucine, valine, methionine, 
threonine, and histidine) move from the circulation across the blood brain barrier through 
sodium-independent diffusion (Choi and Pardridge 1986) facilitated by the LNAA 
transporter LAT1 (also designated SCLA7A5), a member of the APC family of 
transmembrane transport proteins (Kanai et al. 1998; Mastroberardino et al. 1998). LAT1 
is expressed on both the luminal (blood side) and the abluminal (extra cellular fluid 
(ECF) side) of the brain capillary endothelial cell (Sanchez del Pino et al. 1995) and 
mediates movement of LNAA down a concentration gradient from blood through the 
endothelial cell and to the ECF compartment. The affinity of the LAT1 transporter for 
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LNAA is high relative to blood concentrations of the amino acids (Km  20-200 µM) 
suggesting that at normal physiologic plasma LNAA concentrations the LAT1 transporter 
is already saturated. However, in this study brain Phe content never appeared to 
saturate despite massively increased blood Phe suggesting that, during the 
hyperphenylalaninemic state at least, Phe uptake into brain is mediated through some 
other mechanism beyond LAT1-mediated facilitated diffusion.  
 
Tyrosine (Tyr) is the product of the PAH reaction and the substrate for dopamine 
synthesis. In PAH-deficient mice and humans, Tyr becomes a dietary essential amino 
acid as it is no longer synthesized from Phe. As expected serum Tyr concentration 
(Figure 2D) was significantly decreased in both male and female Pah-/- mice (36 ± 3 µM 
and 44 ± 3 µM respectively) in comparison to Pah+/+ (male = 72 ± 4 µM, female = 91 ± 4 
µM) or Pah+/- (male = 57.5 ± 3.6 µM, female = 56.6 ± 5.4 µM) mice. However, despite 
the greater than 50% decrease in blood Tyr and the massively increased blood Phe of 
hyperphenylalaninemic mice, brain Tyr content (Figure 2E) was not significantly 
decreased in these animals. Brain Tyr in Pah-/- mice (male = 79 ± 18 nmol/gm, female = 
91 ± 13 nmol/gm) was not significantly different from that of Pah+/+ (male = 101 ± 22 
nmol/gm, female = 88 ± 11 nmol/gm) or Pah+/- (male = 173 ± 18 nmol/gm, female = 163 
± 20 nmol/gm) animals. Furthermore, analyses of brain Tyr vs. serum Tyr (r2 = 0.013) or 
of brain Tyr vs. serum Phe (r2 = 0.059) failed to demonstrate any significant correlations 
(not shown). 
 
In dopaminergic neurons, Tyr is converted to dopamine with the rate of conversion 
limited by the activity of tyrosine hydroxylase (TH) enzyme (Figure 1). Following 
synaptic release and signal transmission, dopamine may either be taken back up into 
the axon of the dopaminergic neuron via a dopamine-specific transporter (DAT) or 
enzymatically converted to homovanillic acid (HVA). Impairment of systemic Tyr 
synthesis in PKU has led to the hypothesis that CNS dopamine deficiency contributes to 
the neurobehavioral phenotypes associated with PKU. However, in our study, HPA and 
serum Tyr deficiency were associated with only minimal impairment of dopamine 
synthesis and turnover. Two-way ANOVA revealed an effect of genotype (p < 0.0001) 
upon brain dopamine content, but post hoc group comparisons of the normalized data 
demonstrated a significant difference in brain dopamine only between female Pah+/+ 
and female Pah-/- mice (p < 0.01) (Figure 2F). In that comparison, female Pah+/+ brain 
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dopamine content was on average 55% higher than that of female Pah-/- mice. For 
males, a trend for 21% higher brain dopamine in Pah+/+ mice than in Pah-/- animals 
was measured. The brain contents of HVA (Figure 2G) of female Pah+/+ and Pah+/- 
mice were on average 65% and 69% greater (p < 0.0001) respectively than that of Pah-
/- mice, whereas for males, only a trend (26% and 14% higher for Pah+/+ and Pah+/- 
mice, respectively) was measured. Recalling that brain Tyr content was not significantly 
different among the different genotypes and that brain Phe concentrations were higher in 
female than in male Pah-/- mice, these data suggest that Phe-mediated competitive 
inhibition of TH activity rather than substrate availability is likely responsible for the 
minimal deficiency in brain dopamine content and turnover measured in 
hyperphenylalaninemic (and particularly in female) Pah-/- mice. 
 
Serotonin is synthesized in the serotonergic neurons from L-tryptophan (Trp) via the 
rate-limiting enzyme, TPH isoform 2 (TPH2). We measured a less than twofold increase 
in serum Trp concentration of female Pah+/+ mice (118 ± 4.6 µM) in comparison to male 
Pah+/+ mice (69 ± 2.5 µM) or to Pah+/- (89 ± 3.4 µM) or Pah-/- (78 ± 2.6 µM) female 
mice (Figure 2H). These differences are unexplained as no such differences were seen 
in comparing male Pah+/+ (69 ± 2.5 µM), Pah+/- (82 ± 6.3 µM) or Pah-/- (68 ± 2.5 µM) 
mice. Brain Trp content was not significantly different between the genotypes or sexes 
(Figure 2I). As was true for Tyr, there was no clear correlation between brain Trp and 
serum Trp or brain Trp and serum Phe (data not shown). 
 
The brain content of serotonin (Figure 2J) and its metabolite 5-hydroxyindoleacetic acid 
(5-HIAA) (Figure 2K) was severely decreased in hyperphenylalaninemic mice, of both 
sexes, in comparison to either Pah+/+ or Pah+/- mice. In female mice, brain serotonin 
was on average 240% greater in Pah+/+ and 310% greater in Pah+/- than in Pah-/- 
mice. Similarly, male Pah+/+ mice exhibited 192% and male Pah+/- mice 244% greater 
brain serotonin content than male Pah-/- mice. Similar results were found for brain 5-
HIAA content. Mean brain 5-HIAA contents of female Pah+/+ (519%) and female Pah+/- 
(564%) were dramatically higher than in female Pah-/- mice. Likewise, male Pah+/+ 
(347%) and Pah+/- (413%) brain 5-HIAA contents were significantly greater than that of 
Pah-/- mice. 
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The severe deficiency of the brain serotonin pathway in Pah-/- mice is associated with 
extreme HPA and elevated brain Phe content but normal brain Trp content. Our 
interpretation of these data, similar to our conclusions from the dopamine pathway data, 
is that Phe-mediated competitive inhibition of brain TPH2 activity rather than deficiency 
of the substrate L-tryptophan is primarily responsible for serotonin deficiency in murine 
PKU.  
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Figure 2. Effects of genotype upon amino acids and monoamine neurotransmitters in C57BL/6-Pahenu2/enu2 mice. 
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Serum and brain amino acids and brain monoamine neurotransmitter content in female (F) and male (M) Pah+/+, Pah+/-, Pah-/- 
mice. Data expressed as mean ± SEM. The data were analyzed using two-way ANOVA with post hoc intergroup comparisons by 
Tukey’s multiple comparison test. Horizontal bars and asterisks above the columns indicate the probability (p) from the Tukey’s test 
that the means of the selected groups are identical. **** p < 0.0001, ** p < 0.01, * p < 0.05. Serum amino acid concentrations are 
expressed as µM, brain amino acid content as nmol/gm brain wet weight, and brain monoamine neurotransmitters and their 
metabolites are expressed relative to the mean of untreated Pah-/- mice (both genders combined). (A) Serum phenylalanine, (B) 
brain phenylalanine. (C) Plot of brain phenylalanine vs. serum phenylalanine combining data from all groups of mice (including Pah-/- 
mice undergoing Phe-reducing treatment). Linear regression analysis reveals a probability of p < 0.0001 that the slope of the curve is 
equal to zero and suggests a strong correlation between the serum and brain phenylalanine concentrations. (D) Serum tyrosine, (E) 
brain tyrosine, (F) relative brain dopamine, (G) relative brain homovanillic acid (HVA), (H) serum tryptophan, (I) brain tryptophan, (J) 
relative brain serotonin, (K) relative brain 5-hydroxyindoleacetic acid (5-HIAA). 
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3.2 Lifelong exposure to HPA in untreated adult Pahenu2/enu2 mice is associated with 
altered exploratory activity in the open field and in the fear conditioning 
enclosure, and deficits in nesting behavior and task learning in the water maze. 
Prior to euthanasia for the above biochemical evaluations, detailed behavioral and 
cognitive assessments of all experimental mice were carried out. These assessments 
included nest building behavior and performance in the open field, on the rotorod, in the 
water maze, in a passive avoidance test, and in the contextual and cued fear 
conditioning tests. Comparison of these results in Pah-/- mice to those of Pah+/+ and 
Pah+/- mice revealed significant behavioral effects of chronic HPA only upon exploratory 
activity measured in the open field (Figure 3A), baseline average motion in the fear 
conditioning enclosure (Figure 3C), and upon nesting behavior (Figure 3D). Additional 
effects of chronic HPA were seen in task learning in the Morris water maze (Figures 4B, 
4C, and 4D). In the open field, two-way ANOVA revealed an effect of genotype (p < 
0.0001) and a trend toward an effect of sex (p = 0.0509) upon the distance moved. Post 
hoc Tukey’s multiple comparisons revealed that Pah+/- mice moved more than Pah+/+ 
(p < 0.001) and Pah-/- (p < 0.01) mice. There were no effects of either genotype or sex 
upon the % time spent in the center of the open field, a measure of open field anxiety 
(Figure 3B). In the fear conditioning enclosure, there was also a genotype effect (p < 
0.0001). Pah-/- mice moved less than Pah+/+ (p < 0.0001) and Pah+/- mice (p < 0.0001) 
(Figure 3C). Thus, as in the open field, Pah-/- mice moved less than Pah+/- mice, but 
unlike in the open field, there were no differences in activity between the Pah+/+ and 
PAH+/- mice. This difference might be due to the differences between an open and a 
closed environment and in the different floor types involved in these two distinct tests. 
There was an effect of genotype on nest building (p = 0.0014) (Figure 3D). PAH-/- mice 
built less elaborate nests than PAH+/- mice (p < 0.01) or PAH+/+ mice (p < 0.05). Negative 
results from the other assessments are not specifically reported in detail here. 
 
Water maze testing of untreated Pah-/- mice demonstrated severe cognitive deficits in 
the animals (Figures 4B, 4C, and $D) with a significantly increased total distance 
moved and cumulative to and time to reach (latency) the visible platform for Pah-/- 
animals. First, average swim speeds were analyzed to determine if differences in swim 
speeds accounted for the differences in task performance (Figure 4A). A two-way 
ANOVA did not show any significant differences between the genotypes (p = 0.149) or 
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sexes (p = 0.585), suggesting that the performance differences seen were not due to 
group differences in swim speeds. Two-way ANOVA revealed effects on cumulative 
distance to the platform of both genotype (p < 0.0001) and sex (p = 0.021), with an 
interaction between genotype and sex (p = 0.024). Post hoc comparison revealed 
significant differences between all genotypes (Pah+/+ vs. Pah+/- - p = 0.014, Pah+/+ vs. 
Pah-/- - p < 0.0001, and Pah+/- vs. Pah-/- - p < 0.0001). Similar results were obtained for 
latency with effects of genotype (p < 0.0001), sex (p = 0.008), and an interaction 
between genotype and sex (p = 0.013), and similar differences between all genotypes in 
the post hoc comparisons. Females showed a higher cumulative distance to the visible 
platform, indicative of reduced cognitive performance, compared to males. Analysis of 
total distance moved again showed similar results, with effects of genotype (p < 0.001) 
and sex (p = 0.015). Overall, the results document severe cognitive impairments in 
chronically hyperphenylalaninemic Pah-/- mice.
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Figure 3. Behavioral performance of C57BL/6-Pahenu2/enu2 mice. 
 
Results of behavioral (open field, fear conditioning, and nesting behavior) assessments 
in female (F) and male (M) Pah+/+, Pah+/-, and Pah-/- mice. The results of the 
behavioral performance in the open field are presented in panel (A) open field activity 
(total distance moved) and (B) open field anxiety (% time in center). Baseline activity 
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while in the fear conditioning enclosures is shown in panel (C). Nest building (qualitative 
nest rating scale) is presented in panel (D). All data are mean ± SEM. Pah+/- mice 
showed higher activity levels than Pah+/+ mice and Pah-/- mice in the open field. Pah+/+ 
and Pah+/- mice both showed higher baseline activity than Pah-/- mice in the fear 
conditioning enclosure. Pah-/- mice build less elaborate nests than Pah+/- mice and 
Pah+/+ mice. In Pah-/- mice, females built more elaborate nests than males. Pah+/+ and 
Pah+/- mice showed better nesting behavior than Pah-/- mice (p < 0.05, p < 0.01, 
respectively). Vertical bars and asterisks above the columns indicate the probability (p) 
from the Tukey’s test that the means of the selected groups are identical. **** p < 
0.0001, ** p < 0.01, * p < 0.05.  
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Figure 4. Cognitive performance of C57BL/6-Pahenu2/enu2 mice. 
 
 
Performance in the water maze is presented with both sexes combined. The results are 
shown in panel (A) average velocity (cm/second), (B) latency to the target platform 
(seconds) (C) cumulative distance to the target (cm) and (D) total distance moved (cm). 
The data are represented as mean ± SEM for each experimental group at each 
individual session. (A). There were no differences in swim speeds over the five sessions 
(p > 0.05). (B). Latency to locate the target platform in the water maze. Pah+/+ mice 
showed better performance than Pah+/- (p = 0.020) and Pah-/- mice (p = 0.001) and 
located the platform in less time. In addition, Pah+/- mice showed better performance 
than Pah-/- mice (p < 0.001). (C) Similar results were seen when cumulative distance to 
the target location was analyzed. Pah+/- mice showed better performance than Pah-/- 
mice (p < 0.001) and swam on average closer to the platform location. There was a 
genotype x session interaction (F(8,224) = 3.057, p = 0.003). There was an effect of 
genotype in all Sessions (Session 1: Pah+/+ vs Pah-/-, p < 0.001; Pah+/+ vs Pah+/- p = 
0.009; Session 2: Pah+/+ vs Pah-/-, p < 0.001; Pah+/- vs Pah-/-, p = 0.003; Session 3: 
Pah+/+ vs Pah-/-, p = 0.000; Pah+/- vs Pah-/-, p < 0.001; Session 4: Pah+/+ vs Pah-/-, p 
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< 0.001; Pah+/- vs Pah-/-, p < 0.001; Session 5: Pah+/+ vs Pah-/-, p < 0.001; Pah+/- vs 
Pah-/-, p < 0.001). In the Pah-/- mice, females showed a higher cumulative distance to 
the platform than males. (D) Analysis of the total distance moved confirmed the results 
of the other outcome measures. Both Pah+/+ and Pah+/- mice showed better 
performance than Pah-/- mice (p < 0.001). The asterisks denote sessions in which 
performance of the experimental group (Pah+/- or Pah-/-) differed significantly from 
those of Pah+/+ mice. 
 
 
3.3 Reduction of blood and brain Phe through either dietary phenylalanine 
restriction or liver-directed gene therapy ameliorates brain monoamine 
neurotransmitter deficiency in murine PKU. 
We evaluated the effectiveness of two different blood Phe reducing treatment methods, 
either dietary Phe restriction or liver-directed gene therapy with a PAH expressing 
recombinant adeno-associated virus pseudotype 8 (rAAV2/8) vector (Harding et al. 
2006) for their ability to correct amino acid abnormalities and brain monoamine 
neurotransmitter deficiencies in Pah-/- mice. Gene therapy treated mice received a 
single portal vein injection of rAA2/8 vector (2.5 X 1011 vector genomes (vg) per mouse) 
at 8 weeks age and no additional therapy until euthanasia at 18-20 weeks age, while diet 
treated mice were maintained on a Phe-restricted diet from 8 weeks age until euthanasia 
at 18-20 weeks. The effects of therapeutic intervention upon the serum and brain 
aromatic amino acids and brain monoamine neurotransmitters of Pah-/- mice are 
depicted in Figure 5 and reported in Supplementary Table 2. Both treatment approaches 
significantly reduced serum (Figure 5A) and brain Phe (Figure 5B) in both sexes. In the 
dietary treatment group, serum Phe concentration was reduced from 2198 ± 71 µM to 
295 ± 67 µM in male Pah-/- mice (p < 0.0001) and from 2654 ± 87 µM to 494 ± 111 µM 
in female Pah-/- mice (p < 0.0001). Consequently, brain Phe content was also reduced 
(male Pah-/- mice: untreated – 713 ± 18 nmol/gm, diet treated – 244 ± 17 nmol/gm, p < 
0.0001; female Pah-/- mice: untreated – 811 ± 17 nmol/gm, diet treated – 326 ± 41 
nmol/gm, p < 0.0001). Liver-directed gene therapy at the vector dose used was 
somewhat less and more variably effective in correcting serum Phe concentrations 
(rAAV2/8-treated male Pah-/- mice – 407 ± 175 µM with a range of 191-925 µM, 
rAAV2/8-treated female Pah-/- mice – 961 ± 220 µM with a range from 248-1780 µM) in 
comparison to dietary therapy but these decreases were still highly significant (p 
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<0.0001). Brain Phe content was also decreased (p < 0.0001) in rAAV2/8-treated mice 
(rAAV2/8-treated male Pah-/- mice – 206 ± 41 nmol/gm; rAAV2/8-treated female Pah-/- 
mice - 408 ± 72 nmol/gm). At euthanasia four months after rAAV2/8 injection, the mean 
number of rAAV2/8 vector genomes (vg) detected in total DNA extracted from a liver 
biopsy and measured by quantitative PCR was only 2.6 ± 0.6 vg per haploid liver 
genome (mean ± SE). Mean liver PAH activity in male rAAV2/8-treated mice was 10.4% 
± 0.4% (mean ± SE) of wild type liver PAH activity and only 7.6% ± 0.3% in female 
rAAV2/8-treated mice. Liver PAH activity in untreated Pah-/- mice was below the limit of 
detection for this radiometric assay (1% wild type liver PAH activity) as we have 
previously reported (Harding et al. 1998) . In our initial work with rAAV2/8 gene therapy 
(Harding et al. 2006), serum Phe was corrected to wild type levels only in mice that had 
received a rAAV2/8 vector dose > 5 X 1011 vg/mouse yielding liver rAAV2/8 vg copy 
number > 25 vg/haploid liver genome and liver PAH activity greater than approximately 
10% wild type liver PAH activity. In this experiment, the lower rAAV2/8 dose we 
employed was associated with only partial restoration of liver PAH activity and serum 
Phe concentrations that were significantly decreased but still above the normal range. 
Neither dietary Phe restriction nor liver-directed gene therapy in this experiment led to 
correction of blood or brain Phe down to concentrations measured in Pah+/+ or Pah+/- 
mice; however, the serum Phe levels achieved with diet therapy are in line with the 
typical therapeutic goal of reducing serum phenylalanine to below 360 µM in humans 
with PKU (Vockley et al. 2014). 
 
Reduction of blood phenylalanine by either treatment method is associated with reversal 
of HPA-associated hypopigmentation in the mice (Figure 5C). Hypopigmentation in PAH 
deficiency is caused by Phe-mediated competitive inhibition of the melanin synthesis 
enzyme tyrosinase (Miyamoto and Fitzpatrick 1957); correction of HPA releases 
tyrosinase inhibition and restores melanin synthesis. 
 
Despite the variable effect of rAAV2/8 administration upon serum and brain Phe, liver-
directed gene therapy yielded complete correction of serum Tyr in treated Pah-/-mice 
(Figure 5D) (rAAV2/8-treated male Pah-/- mice – 98.3 ± 9.5 µM vs. 35.9 ± 3.0 µM in 
untreated mice (p <0.0001); rAAV2/8-treated female Pah-/- mice – 86.4 ± 9.8 µM vs. 
44.1 ± 3.1 µM in untreated female Pah-/- mice (p < 0.0001)). Liver-directed gene therapy 
restores liver PAH activity and therefore restores systemic Tyr synthesis. Despite 
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leading to more robust correction of HPA in comparison to gene therapy, dietary Phe 
restriction with the diet formulation used here did not lead to significant improvement in 
blood Tyr concentration of Pah-/- mice (diet treated male Pah-/- mice – 31.2 ± 3.4 µM; 
diet-treated female Pah-/- mice – 31.7 ± 2.4 µM), results that were not statistically 
different from those of untreated Pah-/- mice. The standard mouse chow utilized in our 
lab contains 0.71% Tyr (as part of intact dietary protein) but the Phe-free diet we used 
contained only 0.5% Tyr with the Tyr added to the chow as the free amino acid. The 
aromatic amino acids including Tyr are relatively insoluble in water in comparison to 
other amino acids, and therefore free Tyr added to mouse chow may be less available 
for intestinal absorption in comparison to Tyr released from digested whole protein. For 
all these reasons, persistently low serum Tyr concentration in Pah-/- mice on the Phe-
restricted diet is understandable. 
 
Although serum Tyr increased significantly in rAAV2/8-treated mice, the brain Tyr 
content was not appreciably altered by liver-directed gene therapy, nor by dietary Phe 
restriction (Figure 5E). Despite that, treatment did still yield a slight but significant effect 
upon brain dopamine (Figure 5F) and HVA (Figure 5G) content. In females, brain 
dopamine content increased 69% on average in diet treated mice in comparison to 
untreated mice (p < 0.01). Dopamine increased 39% on average in rAAV2/8-treated 
female mice, 14% in rAAV2/8-treated male mice, but was virtually unchanged in diet-
treated male mice. None of these latter changes reached statistical significance by post 
hoc group comparisons however. Brain HVA increased by 60% on average in diet-
treated female Pah-/- mice (p < 0.01), 37% in rAAV2/8-treated females, 4% in diet 
treated males, and 8% in rAAV2/8-treated males. Again, none of the differences in these 
last three groups were found to be statistically significant. 
 
Both dietary Phe restriction and rAAV2/8-mediated gene therapy were associated with 
slight increases in serum Trp (Figure 5H) of Pah-/- mice. Serum Trp concentration 
increased from 78.3 ± 2.6 µM in untreated female Pah-/- mice to 108 ± 5.5 µM in female 
Pah-/- (p < 0.0001) on the Phe-restricted diet and to 100 ± 3.2 µM in female Pah-/- mice 
(p < 0.001) after gene therapy. Trp is an essential amino acid that cannot be synthesized 
in the body and must be obtained through dietary intake, so these results suggest that 
lower blood Phe is associated with either improved intestinal Trp uptake or altered liver 
release of Trp into blood. However, serum Trp concentrations were only modestly 
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increased in treated male Pah-/- mice (untreated male Pah-/- mice – 68.4 ± 2.5 µM, male 
Pah-/- mice on Phe-restricted diet – 85.6 ± 3.2 µM (p < 0.05), male Pah-/- mice following 
gene therapy – 86.3 ± 2.9 µM (difference not significant). Regardless of whether this 
apparent effect of treatment upon serum Trp, primarily in female mice, is real, neither 
treatment had any significant effect upon brain Trp content (Figure 5I).   
 
Dietary Phe restriction was associated with complete correction of brain serotonin 
(Figure 5J) and 5-HIAA (Figure 5K) content in Pah-/- mice. In female Pah-/- mice, brain 
serotonin content increased on average by 322% (p < 0.0001) and brain 5-HIAA content 
increased by 588% (p < 0.0001) in animals receiving the Phe-restricted diet in 
comparison to untreated Pah-/- mice. Similar increases were measured in treated male 
Pah-/- mice (brain serotonin: 218% increase on average in diet-treated mice (p < 0.01); 
brain 5-HIAA: 398% increase (p < 0.0001)). Brain serotonin and 5-HIAA content in diet 
treated female Pah-/- mice (mean brain serotonin = 151 ± 28 pmol/mg protein; mean 
brain 5-HIAA = 124 ± 30 pmol/mg) exceeded that of wild type female Pah+/+ animals 
(brain serotonin = 80 ± 2.9 pmol/mg; brain 5-HIAA = 73 ± 5.5 pmol/mg). Similarly, brain 
serotonin and 5-HIAA in diet-treated male Pah-/- mice (brain serotonin = 110 ± 7.2 
pmol/mg, brain 5-HIAA = 87 ± 12 pmol/mg) were approximately equal to or greater than 
levels in Pah+/+ mice (brain serotonin = 75 ± 6.2 pmol/mg, brain 5-HIAA = 51 ± 2.3). 
These results indicate that reduction of blood and brain Phe in diet treated Pah-/- mice 
was associated with complete correction of CNS serotonin deficiency.  
 
Brain serotonin and 5-HIAA contents were also increased in Pah-/- mice treated with 
rAAV2/8-mediated gene therapy (serotonin: female mice – 65.9 ± 14.9 nmol/mg, male 
mice – 59.5 ± 3.3 nmol/mg; 5-HIAA: female mice – 36.2 ± 6.2 nmol/mg, male mice – 
34.1 ± 2.5 nmol/mg), but the increase was not as robust as seen in the diet-treated 
group. Average brain serotonin increased 208% (p < 0.05) in rAAV2/8-treated female 
mice but only 166% in male mice, a difference that did not reach statistical significance. 
Similarly, average brain 5-HIAA increased 237% in rAAV2/8-treated female mice. As 
discussed above, serum Phe concentration was on average higher in mice treated with 
rAAV2/8-mediated gene therapy in comparison to animals on the Phe-restricted diet; we 
propose therefore that the partial correction of blood and brain Phe following treatment 
with rAAV2/8 vector was responsible for the improved but persistently low brain 
serotonin and 5-HIAA in comparison to diet-treated mice. 
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In combining data from all experimental groups, we measured significant negative 
correlations between brain serotonin and serum Phe, and between brain serotonin and 
brain Phe (Supplemental figure 1).  
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Figure 5. Effects of phenylalanine-reducing treatments upon amino acids and monoamine neurotransmitters in C57Bl/6-
Pahenu2/enu2 mice. 
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Serum and brain amino acids and brain monoamine neurotransmitter content in female (F) and male (M) untreated Pah-/- mice (Pah-
/-), Pah-/- mice receiving a phenylalanine-restricted diet (Pah -/- low Phe diet), and Pah-/- mice following AAV-mediated liver-
directed gene therapy (Pah-/- AAV8). Data expressed as mean ± SEM. The data were analyzed using two-way ANOVA with post 
hoc intergroup comparisons by Tukey’s multiple comparison test. Horizontal bars and asterisks above the columns indicate the 
probability (p) from the Tukey’s test that the means of the selected groups are identical. **** p < 0.0001, ** p < 0.01, * p < 0.05. 
Serum amino acid concentrations are expressed as µM, brain amino acid content as nmol/gm brain wet weight, and brain 
monoamine neurotransmitters and their metabolites are expressed relative to the mean of untreated Pah-/- mice (both genders 
combined). The gray line labeled +/+ represents the mean of wild type Pah+/+ mice (both genders combined) for comparison. (A) 
Serum phenylalanine, (B) brain phenylalanine, (D) serum tyrosine, (E) brain tyrosine, (F) relative brain dopamine, (G) relative brain 
homovanillic acid (HVA), (H) serum tryptophan, (I) brain tryptophan, (J) relative brain serotonin, (K) relative brain 5-
hydroxyindoleacetic acid (5-HIAA). (C) Photograph of an untreated Pah-/- mouse (Pahenu2) and a Pah-/- mouse eight weeks after 
receiving rAAV2/8-mediated liver-directed gene therapy (AAV8) demonstrating the change in coat color associated with 
normalization of blood Phe concentration. 
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Supplementary Figure 1. Correlations between brain tryptophan, serum 
phenylalanine, or brain phenylalanine and the serotonin axis. 
 
 
Correlations between brain serotonin or 5-HIAA (pmol/mg protein) and brain tryptophan 
(nmol/gm wet weight), serum phenylalanine (µM), or brain phenylalanine (nmol/g wet 
weight). Linear regression analysis was carried out for each data set. Goodness of fit (r2) 
and the probability (p) that the slope of the regression line equals zero are depicted on 
each chart. (a) Brain serotonin vs. brain tryptophan, (b) brain 5-HIAA vs. brain 
tryptophan, (c) brain serotonin vs. serum phenylalanine, (d) brain 5-HIAA vs. serum 
phenylalanine, (e) brain serotonin vs. brain phenylalanine, (f) brain 5-HIAA vs. brain 
phenylalanine.
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3.4 Reduction of blood and brain phenylalanine is associated with improvements 
in open field activity and nesting behavior but little change in memory deficits of 
Pahenu2/enu2 mice.  
Phe-reducing treatment was associated with significant improvements in open field 
activity and nesting behavior but had only a minor effect upon the cognitive deficits. 
Analysis of distance moved in the open field (Figure 6A) revealed an effect of treatment 
(p = 0.0032), but no effect of sex (p = 0.1108), and no interaction between treatment and 
sex. However, post hoc Tukey’s multiple comparison demonstrated a significant 
difference only between Pah-/- and Phe-restricted diet treated Pah-/- mice (p < 0.01); a 
trend for a positive effect of rAAV2/8 gene therapy was only observed in females. There 
were no significant effects of treatment upon measures of anxiety in the open field, as 
measured by the % time spent in the center of the open field (Figure 6B). Similar 
differences in movement were seen in the fear conditioning enclosure (Figure 6C). 
Analysis of baseline motion, prior to any tone or shock exposure, revealed a significant 
treatment effect (p = 0.0049) but no effect of sex (p = 0.9296) or treatment by sex 
interaction. Untreated Pah-/- mice moved less than Pah-/- mice on low Phe diet (p < 
0.01) and Pah-/- receiving AAV8 (p < 0.01).  
 
In Pah-/- mice, there also was an effect of treatment on nest building (p = 0.045, Figure 
6D). Nest building was more elaborate in Pah-/- mice that received AAV8 than those that 
received a low Phe diet (p = 0.035). In Pah-/- mice there was also an effect of sex on nest 
building (p = 0.011), with more elaborate nest building in female than male mice. 
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Figure 6. Effects of Phe-reducing treatments on behavioral testing in C57BL/6-
Pahenu2/enu2 mice.  
 
Results of behavioral performance in the open field, fear conditioning chamber, and 
nesting behavior of female (F) and male (M) untreated Pah-/- mice, Pah-/- mice 
receiving a phenylalanine-restricted diet (PAH -/- low Phe diet), and Pah-/- mice 
following AAV-mediated liver-directed gene therapy (PAH-/- AAV8). The results of the 
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behavioral performance in the open field are presented in panel (A) activity in the open 
field (total distance moved) and (B) measures of anxiety in the open field (% time in 
center). Baseline activity while in the fear conditioning enclosure is shown in panel (C). 
Nest building (qualitative nest rating scale) is presented in panel (D). All data are 
expressed as mean ± SEM. (A) In Pah-/- mice, higher activity levels were seen in mice 
on a low Phe diet compared to those on a regular diet in the open field enclosure. (B) 
There were no effects of treatment on measures of anxiety in the center of the open 
field. (C) Baseline activity in the fear conditioning enclosure showed similar treatment 
effects. Pah-/- mice moved less than Pah-/- mice treated with low Phe diet and Pah-/- 
treated with AAV8. (D) Pah-/- mice treated with AAV8 showed more complex nest 
building than Pah-/- mice treated with low Phe diet. Vertical bars and asterisks above the 
columns indicate the probability (p) from the Tukey’s test that the means of the selected 
groups are identical. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05. 
 
 
Liver gene therapy with rAAV2/8 was associated with a small improvement in cognitive 
performance of Pah-/- mice as measured by ability to reach the visible platform in the 
water maze. Two-way ANOVA revealed effects of both treatment (p = 0.002) and sex (p 
= 0.001) for cumulative distance to the visible platform in the water maze (Figure 7C), 
with differences between rAAV2/8-treated and untreated Pah-/- mice (p = 0.02) and 
between rAAV2/8 treated and diet treated Pah-/- mice (p = 0.006) by post hoc multiple 
group comparisons. In addition, females showed a higher cumulative distance to the 
visible platform than males. Similar results were seen when latency was used as 
performance measures (Figure 7B). Trends in improved cognitive performance among 
diet treated Pah-/- mice were observed but did not reach statistical significance. 
However, these effects were not seen when total distance moved was analyzed as 
performance (Figure 7D). When average swim speeds were analyzed, there was a 
significant effect of genotype (p = 0.001), with Pah-/- treated with AAV8 swimming faster 
than untreated Pah-/- (p = 0.007) and Pah-/- diet-treated mice (p = 0.001). Thus, 
enhanced swim speeds and motor function might have contributed to the improvement 
in water maze performance.  
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Figure 7. Effects of Phe-reducing treatments on cognitive testing in C57BL/6-
Pahenu2/enu2 mice.  
 
 
Results of cognitive performance in the Morris water maze of female and male untreated 
Pah-/- mice, Pah-/- mice receiving a phenylalanine-restricted diet (PAH -/- low Phe 
diet), and Pah-/- mice following AAV-mediated liver-directed gene therapy (PAH-/- 
AAV8). The results of water maze testing are presented in panel (A) average velocity 
(cm/second), (B) latency to the target platform (seconds), (C) cumulative distance to the 
target (cm), and (D) total distance moved (cm) with results shown for both sexes 
combined. (A) PAH-/- mice that received AAV8 swam faster than both Pah-/- untreated 
and Pah-/- low Phe diet mice. (B) When latency to locate the platform was analyzed, 
there was a significant treatment effect in the second session. (C) Pah-/- mice that 
received AAV8 showed better performance than genotype-matched mice that received 
no treatment (p = 0.020) or a low Phe diet (p = 0.006) and significant treatment effects 
were seen in the first and second sessions. (D) Analyzing total distance moved did not 
reveal any differences between the treatment groups. The data are represented as 
mean ± SEM for each experimental group at each individual session. For the treatment 
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effects, asterisks denote sessions in which results in the treatment groups differed 
significantly from that of untreated Pah-/- mice. 
 
 
Cumulatively, these data argue that the behavioral phenotype of hyperphenylalaninemic 
mice is partly reversible even though the animals had not been treated until adulthood. 
Nesting behavior in mice, an indicator of health and welfare involving limbic and frontal 
cortical areas (Gaskill et al. 2013), may be construed as a function analogous to 
attention, executive functioning, and activities of daily living in humans (Deacon 2006; 
Torres-Lista and Gimenez-Llort 2013; Heller et al. 2014; Jirkof 2014). HPA in previously 
well treated adult humans with PKU is known to be associated with significant 
impairment of executive functioning with abundant evidence that these problems are 
related to concurrent HPA and are reversible with improved dietary Phe control 
(VanZutphen et al. 2007; Christ et al. 2010; Huijbregts et al. 2013; Jahja et al. 2013). In 
our experiment, improvements in nesting behavior with Phe-reducing treatment were 
associated with increased brain dopamine and serotonin. Administration of dopamine 
and serotonin reuptake inhibitors to female rats after gestation has been shown to be 
associated with increased frequency of nesting behavior (Johns et al. 2005). We 
hypothesize that increased brain monoamine neurotransmitter content in treated Pah-/- 
mice was specifically responsible for the behavioral improvements, but our study cannot 
directly prove this hypothesis. Further experiments to specifically manipulate CNS 
dopamine and serotonin content without altering blood and brain Phe will be needed to 
critically evaluate the connection between behavioral impairments and CNS monoamine 
neurotransmitter deficiency in Pahenu2/enu2 mice. 
 
Clearly, however, significant cognitive limitations continue to exist in treated Pah-/- mice, 
presumably because HPA during the juvenile period severely and permanently altered 
brain development. The adult Pah-/- mice, whether treated or not, exhibit significantly 
decreased brain weight in comparison to Pah+/+ mice (male Pah+/+ mean brain weight 
= 442 ± 9 mg vs. male Pah-/- = 391 ± 3 mg (p < 0.0001), female Pah+/+ = 448 ± 5 mg 
vs. female Pah-/- = 378 ± 4 mg (p < 0.0001)). Neuropathological evaluation of the 
untreated adult Pah-/- mouse brain shows disturbances of white matter integrity (Dyer et 
al. 1996) and decreased complexity of dendritic spine development with fewer synaptic 
connections but normal neuron numbers (Horling et al. 2015). These neuropathological 
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findings are very similar to those described in rare reports of brain histology from 
humans with untreated PKU (Alvord et al. 1950; Malamud 1966; Bauman and Kemper 
1982). Our data strongly suggest that the severe cognitive deficits we and others 
(Zagreda et al. 1999; Cabib et al. 2003; Bruinenberg et al. 2016) have documented in 
Pah-/- mice are likely linked to impaired neuronal development of hyperphenylalaninemic 
juvenile mice that is not reversed by Phe-reducing therapy initiated during adulthood. 
 
3.6 Tyrosine hydroxylase and tryptophan hydroxylase expression is reduced in 
Pahenu2/enu2 brain and is not affected by Phe lowering therapies. 
Correction of brain monoamine neurotransmitter content following Phe-lowering 
treatments in Pah-/- mice could have been mediated by an increase in brain TH or TPH2 
expression leading to improved rates of dopamine and serotonin production. We found 
that the abundance of TH (Figure 8A) and TPH2 (Figure 8C) proteins relative to 
GAPDH as assessed by Western blot was reduced in brain homogenates of Pah-/- mice 
in comparison to wild type animals. Measurement of brain TH (Figure 8B) and TPH 
(Figure 8C) activities assayed in vitro under optimized and maximally stimulated 
conditions demonstrated that adult Pah-/- mice express less TH and TPH2 in brain than 
Pah+/+ mice (see also Supplementary Table 3). TH activity measured in Pah-/- mouse 
half brain homogenate was only 3.63 ± 0.52 pmol/min/mg protein in comparison to 8.87 
± 0.59 pmol/min/mg in wild type mice. Visualization of TH (Figure 8E) abundance in 
striatum using immunohistology confirmed this difference. TPH2 activity was similarly 
reduced in Pah-/- mice (Pah-/- = 6.20 ± 0.56 pmol/min/mg; wild type = 8.82 ± 0.60 
pmol/min/mg). Importantly, reduction of blood and brain Phe, whether through dietary 
Phe restriction or liver-directed gene therapy, was not associated with any significant 
change in brain TH or TPH protein content or maximal activity in Pah-/- mice. Therefore, 
the corrections in brain monoamine content we measured following Phe-reducing 
therapies were not caused by increased production of TH and TPH protein.
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Figure 8. Expression of tyrosine hydroxylase (TH) and tryptophan hydroxylase 
(TPH2) in brain of C57BL/6-Pahenu2/enu2 mice and effects of phenylalanine reducing 
treatments. 
 
The abundance of (A) TH and (C) TPH2 proteins in half brain homogenates from wild 
type mice (5 male, 5 female), untreated Pah-/- mice (5 male, 5 female), and Pah-/- mice 
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(4 male and 4 female in each group) treated with either dietary phenylalanine restriction 
or AAV8 liver gene therapy were measured relative to GAPDH by Western blotting. The 
data are presented as the mean ± SEM TH/GAPDH or TPH/GAPDH ratios. The 
maximally stimulated TH and TPH activities (panels (B) and (D) respectively) in half 
brain homogenates were measured in vitro and the data were expressed as mean ± 
SEM pmol reaction product produced/min/mg brain protein. Differences across groups 
were explored using one-way ANOVA with post hoc Holm-Sidak’s multiple comparisons 
test. Vertical bars and asterisks above the columns indicate the probability (p) from the 
Tukey’s test that the means of the selected groups are identical. **** p < 0.0001, ** p < 
0.01, * p < 0.05.  
TH (panel E, 200 X magnification) abundance in microscopic sections of brain striatum 
was detected by immunohistology and fluorescence microscopy (representative images 
shown). 
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4. DISCUSSION 
4.1 Phe-mediated inhibition of TH and TPH activities is predominantly responsible 
for monoamine neurotransmitter deficiencies in Pahenu2/enu2 mouse brain. 
Given the extreme HPA in Pah-/- mice and putative saturation of the LAT1 transporter, 
we had expected to measure severely decreased brain Tyr and Trp content. However, In 
the experiments reported here and in our previous work (Harding et al. 2014), brain Tyr 
and Trp contents were only minimally reduced in Pah-/- mice in comparison to Pah+/+ 
mice, even though the blood concentrations of these amino acids were low. Also, brain 
Tyr and Trp contents were not substantially altered by Phe-reducing treatment. A 
separate, sodium dependent, energy requiring LNAA transporter with even higher affinity 
(Km  0.2 µM) but lower transport capacity than LAT1 is expressed on the abluminal side 
of the BBB (O'Kane and Hawkins 2003). This system is capable of transporting LNAA 
from ECF to the circulation against the gradient. The two transport systems together 
insure a constant LNAA supply to the brain but with homeostatic control of LNAA flux to 
maintain constant LNAA concentrations in the brain independent of any variation in 
blood LNAA levels (Hawkins et al. 2006). We propose that this homeostatic mechanism 
is capable of maintaining brain Tyr and Trp content despite extremely increased blood 
and brain Phe content in PKU. 
 
In our experiments, values of brain dopamine and serotonin in our experiment correlated 
strongly with either blood or brain Phe content. These data are consistent with a 
previous report that brain serotonin measured through microdialysis of the Pah-/- mouse 
prefrontal cortex were more consistently related to brain Phe than brain Trp (Pascucci et 
al. 2008). Phe-reducing treatment, either dietary Phe restriction or rAAV2/8-mediated 
liver-directed gene therapy, in our hands was associated with near normalization of brain 
monoamine neurotransmitter content and turnover in Pah-/- mice. Furthermore, 
correction of monoamine content was more complete in diet-treated mice that exhibited 
lower blood Phe than in rAAV2/8-treated mice with a greater range of blood Phe 
concentrations, despite the fact that diet-treated mice exhibited persistent blood Tyr 
deficiency. We have also shown here that the abundance of TH and TPH protein is 
constitutively reduced in Pah-/- brain and is unaltered by Phe-reducing therapies initiated 
during adulthood. Additionally, TH activity measured in vivo through the analysis of L-
DOPA production in microdialysates obtained from Pah-/- mouse prefrontal cortex was 
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strongly inhibited in hyperphenylalaninemic mice (Pascucci et al. 2012). Taken together, 
our results along with published data lend greater support to the hypothesis that 
monoamine neurotransmitter deficiency in PKU is predominantly caused by a reduction 
in TH and TPH2 enzymatic levels and Phe-mediated inhibition of both activities rather 
than limited substrate availability.  
 
4.2 Implications for Large Neutral Amino Acid (LNAA) supplementation as therapy 
for PAH deficiency. 
If Phe-mediated inhibition of TH and TPH2 activities is the predominant mechanism 
causing monoamine neurotransmitter deficiency in PKU, then Tyr and Trp 
supplementation alone, without concomitant reductions in blood and brain Phe, will not 
substantially ameliorate CNS monoamine neurotransmitter deficiency in 
hyperphenylalaninemic mice or humans. Dietary Tyr supplementation without dietary 
Phe restriction has been proposed as a potential therapeutic alternative for PKU, 
although interestingly little attention has been paid in the existing literature to the 
possible effects of Trp deficiency. Tyr supplementation as sole therapy for infants with 
PKU without reduction of blood Phe does not prevent severe cognitive disability 
(Batshaw et al. 1981), but oral Tyr supplementation in hyperphenylalaninemic adults, 
some of whom had been late-treated, has been associated with increased cerebrospinal 
fluid (CSF) neurotransmitter levels and improved visual reaction times (Lou et al. 1987; 
Lykkelund et al. 1988). Other investigators however have found no consistent benefit of 
Tyr supplementation among early-treated adults in the context of poor dietary Phe 
control (Pietz et al. 1995).  
 
Oral supplementation with a mixture of LNAA including Tyr and Trp but without dietary 
Phe restriction has been widely advocated as a possible means of preventing Phe-
mediated CNS effects in hyperphenylalaninemic adults with the rationale that LNAA 
would successfully compete against Phe for uptake into brain, lead to lower brain Phe 
content, and restore any CNS metabolic disturbance associated with increased brain 
Phe content (reviewed in (Rocha and Martel 2009)). Several different LNAA mixtures 
formulated as powders or tablets are commercially available for oral treatment of adults 
with PKU. Pietz and colleagues reported that cerebral Phe content as measured by 
proton magnetic resonance spectroscopy following an oral Phe challenge in six adults 
with PKU was significantly reduced by oral supplementation with a mixture of valine, 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 42 
leucine, isoleucine, methionine, tyrosine, histidine, and tryptophan (Pietz et al. 1999). A 
subsequent open label clinical trial of this LNAA mixture plus added histidine and 
arginine was associated with increased blood Tyr and Trp concentration but no effect 
upon blood Phe (Koch et al. 2003). The results of our experiment reported here predict 
little effect upon brain Phe, Tyr, Trp, or monoamine neurotransmitters following 
administration of this LNAA mixture if blood Phe were not altered. However, Schindeler 
and colleagues have demonstrated a positive benefit upon executive function in 
hyperphenylalaninemic adults treated with LNAA in an open label clinical trial even if 
blood Phe was not altered by the therapy (Schindeler et al. 2007). Recent investigations 
in the Pahenu2 mouse suggest that an appropriately designed LNAA mixture could 
improve CNS monoamine neurotransmitter content through three potential mechanisms: 
reduction of brain Phe through competition for transport at the BBB, increased brain Tyr 
and Trp content, and finally reduced inhibition of TH and TPH2 activities (van Vliet et al. 
2015; van Vliet et al. 2016). Careful review of those data reveal that LNAA treatment 
was associated with significant reductions in both blood and brain Phe. Given the results 
of our experiment reported here, we hypothesize that LNAA-mediated reduction in blood 
Phe and consequently reduced brain Phe likely was predominantly responsible for the 
improved brain serotonin content in LNAA-treated Pahenu2 mice. 
 
5. CONCLUSION 
We report that Phe-reducing treatment, either dietary Phe restriction or rAAV2/8-
mediated liver-directed gene therapy, was associated with significantly improved CNS 
neurotransmitter status in Pahenu2/enu2 mice. These data are consistent with a previous 
report of improved brain neurotransmitters following liver-directed gene therapy with an 
adeno-associated virus vector in BTBR-Pahenu2/enu2 mice (Yagi et al. 2012) and a report 
of improved behavior in BTBR-Pahenu2/enu2 mice following treatment with a PAH-
expressing helper dependent adenoviral vector (Cerreto et al. 2012). Improvements in 
brain neurotransmitter content, predominantly of the serotonin axis, correlated primarily 
with serum and brain Phe concentrations and not the brain concentrations of either Tyr 
or Trp, the precursors of dopamine and serotonin respectively. The data suggest that 
Phe-mediated competitive inhibition of TH and TPH2 activities is the predominant 
mechanism behind monoamine neurotransmitter deficiency in hyperphenylalaninemic 
mice. The observed biochemical improvements in Pah-/- mice following Phe-reducing 
therapy initiated at 8 weeks age were associated with improved open field activity and 
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nesting behaviors but without meaningful change in the severe cognitive deficit exhibited 
by the mice. Importantly, there were no genotype differences in swim speeds, excluding 
the possibility that genotype differences in motor function might have contributed to 
genotype difference in performance in the water maze. Prevention of these cognitive 
deficits likely requires initiation of Phe-reducing therapy during early infancy to allow 
normal brain development. Indeed, liver-directed gene therapy administered at 3 weeks 
age has been associated with improved performance in the water maze by BTBR-
Pahenu2/enu2 mice (Cerreto et al. 2012). Although the improvements in activity levels in the 
open field and nesting behavior in our experiment were associated with significantly 
increased brain serotonin content, further experiments will be necessary to investigate 
the specific hypothesis that serotonin deficiency is the proximal molecular mechanism 
causing altered behavioral performance and impaired cognitive function in 
hyperphenylalaninemic Pahenu2/enu2 mice. 
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SUPPLEMENTARY TABLE 1 - Genotype effects 
 
Analyte Pah+/+ 
Mean ± SE 
Pah+/- 
Mean ± SE 
Pah-/- 
Mean ± SE 
Interaction Genotype Sex 
 
 F 
N = 11 
M 
N = 8 
F 
N = 4 
M 
N = 4 
F 
N = 16 
M 
N = 11 
(F) p (F) p (F) p 
 
Serum phenylalanine 
(µM) 
111 ± 11 132 ± 16 72 ±7 98 ± 23 2654 ± 
87 
2198 ± 
71 
 
7.651 0.0013 715.9 < 
0.0001 
4.236 0.0451 
Brain phenylalanine 
(nmol/gm) 
 
85 ± 15 110 ± 28 171 ± 7 194 ± 6 811 ± 17 713 ± 18 6.885 0.0024 753.8 < 
0.0001 
0.8252 0.3682 
Serum tyrosine 
(µM) 
 
91 ± 4 72 ± 4 57 ± 5 57 ± 4 44 ± 3 36 ± 3 2.126 0.1307 61.61 < 
0.0001 
5.495 0.0234 
Brain tyrosine 
(nmol/gm) 
 
88 ± 11 101 ± 22 163 ± 20 173 ± 18 91 ± 13 79 ± 18 0.3774 0.6877 8.131 0.0009 0.05591 0.8141 
Serum tryptophan 
(µM) 
 
118 ± 5 69 ± 3 89 ± 3 82 ± 3 78 ± 3 68 ± 2 18.94 < 
0.0001 
17.22 < 
0.0001 
43.49 < 
0.0001 
Brain tryptophan 
(nmol/gm) 
 
19 ± 2 20 ±4 24 ± 2 25 ±1 17 ± 2 14 ± 2 0.5508 0.5802 4.248 0.0201 0.00144 0.9699 
Dopamine 
(pmol/mg protein) 
 
201 ± 15 203 ± 21 350 ± 54 316 ± 39 156 ± 16 210 ± 19 1.729 0.1884 16.29 < 
0.0001 
0.1226 0.7278 
Homovanillic acid 
(pmol/mg protein) 
 
29 ± 1.3 26 ± 2.1 49 ± 4.1 40 ± 3.2 21 ± 1.7 28 ± 2.1 4.502 0.0161 33.89 < 
0.0001 
1.081 0.3037 
Serotonin 
(pmol/mg protein) 
 
80 ± 2.9 75 ± 6.2 166 ± 4.7 148 ± 12 38 ± 2.4 43 ± 5.3 2.090 0.1348 210.7 < 
0.0001 
1.695 0.1991 
5-HIAA 73 ± 5.5 51 ± 2.3 159 ± 5.5 132 ± 12 17 ± 1.6 22 ± 3.3 8.439 0.0007 321.7 < 14.92 0.0003 
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(pmol/mg protein) 
 
0.0001 
Normalized 
neurotransmitters 
            
Dopamine 
(ratio to mean Pah-/-) 
 
1.44 ± 
0.11 
1.39 ± 
0.15 
1.37 ± 
0.21 
1.23 ± 
0.15 
0.92 ± 
0.07 
1.15 ± 
0.07 
1.477 0.2385 7.544 0.0014 0.0289 0.8658 
Homovanillic acid 
(ratio to mean Pah-/-) 
 
1.53 ± 
0.07 
1.42 ± 
0.12 
 
1.57 ± 
0.13 
1.28 ± 
0.10 
0.93 ± 
0.04 
1.12 ± 
0.06 
4.642 0.0144 24.21 < 
0.0001 
1.039 0.3132 
Serotonin 
(ratio to mean Pah-/-) 
 
2.31 ± 
0.09 
2.10 ± 
0.17 
3.00 ± 
0.18 
2.67 ± 
0.22 
0.97 ± 
0.05 
1.10 ± 
0.07 
2.636 0.0820 148.8 < 
0.0001 
2.059 0.1578 
5-HIAA 
(ratio to mean Pah-/-) 
 
4.93 ± 
0.29 
3.74 ± 
0.20 
5.36 ± 
0.19 
4.45 ± 
0.41 
0.95 ± 
0.06 
1.08 ± 
0.03 
8.326 0.0008 264,7 < 
0.0001 
14.63 0.0004 
P values < 0.05 are highlighted in light blue. 
 
SUPPLEMENTARY TABLE 2 - Treatment effects 
 
Analyte Pah-/- 
Mean ± SE 
Low Phe diet 
Mean ± SE 
AAV8 
Mean ± SE 
Interaction Treatment Sex 
 
 F 
N = 16 
M 
N = 11 
F 
N = 9 
M 
N = 9 
F 
N = 7 
M 
N = 4 
(F) p (F) p (F) p 
 
Serum phenylalanine 
(µM) 
 
2654 ± 
87 
2198 ± 
71 
 
494 ± 
111 
295 ± 67 961 ± 
220 
407 ± 
175 
1.066 0.3525 198.2 < 
0.0001 
15.44 0.0003 
 
Brain phenylalanine 
(nmol/gm) 
 
811 ± 17 713 ± 18 326 ± 41 244 ± 17 408 ± 72 206 ± 41 1.346 0.27 151.9 < 
0.0001 
19.42 < 
0.0001 
Serum tyrosine 
(µM) 
 
44 ± 3 36 ± 3 32 ± 2 31 ± 3 86 ± 10 98 ± 9 1.79 0.1779 65.95 < 
0.0001 
0.0618 0.8047 
Brain tyrosine 91 ± 13 79 ± 18 100 ± 24 80 ± 19 102 ± 15 93 ± 20 0.0384 0.9623 0.1957 0.8229 0.699 0.4073 
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(nmol/gm) 
 
Serum tryptophan 
(µM) 
 
78 ± 3 68 ± 2 107 ± 5 86 ± 3 100 ± 3 86 ± 3 1.629 0.2068 27.25 < 
0.0001 
23.24 < 
0.0001 
Brain tryptophan 
(nmol/gm) 
 
17 ± 2 14 ± 2 23 ± 2 19 ± 2 20 ± 2 16 ± 3 0.0099 0.9901 3.183 0.0503 2.854 0.0976 
Dopamine 
(pmol/mg protein) 
 
156 ± 16 210 ± 19 324 ± 79 227 ± 17 171 ± 15 175 ± 8.2 2.842 0.0682 5.043 0.0103 0.1940 0.6616 
Homovanillic acid 
(pmol/mg protein) 
 
21 ± 1.7 28 ± 2.1 38 ± 9.0 28 ± 2.1 24 ± 2.5 23 ± 1.7 2.138 0.1289 4.142 0.0219 0.2882 0.5939 
Serotonin 
(pmol/mg protein) 
 
38 ± 2.4 43 ± 5.3 151 ± 28 110 ± 7.2 66 ± 15 60 ± 3.3 2.051 0.1398 32.42 < 
0.0001 
1.749 0.1922 
 
5-HIAA 
(pmol/mg protein) 
 
17 ± 1.6 22 ± 3.3 124 ± 30 87 ± 12 36 ± 6.2 34 ± 2.5 1.74 0.1864 29.81 < 
0.0001 
1.195 0.2798 
Normalized 
neurotransmitters 
            
Dopamine 
(ratio to mean Pah-/-) 
 
0.92 ± 
0.07 
1.15 ± 
0.07 
1.56 ± 
0.29 
1.14 ± 
0.07 
1.29 ± 
0.11 
1.32 ± 
0.06 
3.621 0.0343 3.784 0.0298 0.2259 0.6368 
Homovanillic acid 
(ratio to mean Pah-/-) 
 
0.93 ± 
0.04 
1.12 ± 
0.06 
1.49 ± 
0.71 
1.17 ± 
0.07 
1.27 ± 
0.13 
1.21 ± 
0.09 
2.938 0.0626 4.383 0.0179 0.3862 0.5372 
Serotonin 
(ratio to mean Pah-/-) 
 
0.97 ± 
0.05 
1.10 ± 
0.07 
3.11 ± 
0.41 
2.39 ± 
0.12 
2.01 ± 
0.46 
1.82 ± 
0.10 
2.143 0.1284 35.40 < 
0.0001 
1.844 0.1808 
5-HIAA 
(ratio to mean Pah-/-) 
 
0.95 ± 
0.06 
1.08 ± 
0.03 
5.59 ± 
0.69 
4.28 ± 
0.32 
2.25 ± 
0.38 
2.11 ± 
0.16 
3.156 0.0516 92.38 < 
0.0001 
2.587 0.1143 
P values < 0.05 are highlighted in light blue. 
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SUPPLEMENTARY TABLE 3 
 
Brain tyrosine hydroxylase (TH) and tryptophan hydroxylase (TPH2) content 
 
 
Analyte Wild type 
 
n = 10 
PAH -/- 
 
n = 10 
Low Phe 
diet 
n = 8 
AAV8 
 
n = 8 
One way 
ANOVA 
 Mean ± SE Mean ± SE Mean ± SE Mean ± SE 
 
F p 
TH/GAPDH 
ratio 
 
 
4.26 ± 0.35 
 
2.63 ± 0.23 
 
2.55 ± 0.15 
 
3.40 ± 0.40 
 
7.265 
 
0.0008 
TH activity 
(pmol/min/mg) 
 
 
8.87 ± 0.59 
 
3.63 ± 0.52 
 
4.87 ± 0.60 
 
6.24 ± 0.52 
 
17.45 
 
<0.0001 
TPH2/GAPDH 
ratio 
 
 
5.28 ± 0.76 
 
3.67 ± 0.36 
 
2.19 ± 0.37 
 
3.46 ± 0.37 
 
6.487 
 
0.0015 
TPH activity 
(pmol/min/mg) 
 
 
8.82 ± 0.60 
 
6.20 ± 0.56 
 
5.88 ± 0.79 
 
7.32 ± 0.32 
 
5.249 
 
0.0046 
 
TH and TPH2 protein abundance in half brain homogenates (equal numbers of males 
and females in each group) were analyzed by immunoblotting and expressed relative to 
GAPDH. Maximally stimulated TH and TPH activities were measured in half brain 
homogenates as previously described and expressed as pmol product/min/mg brain 
protein. Differences among the four groups in each assay were explored using one-way 
analysis of variance (ANOVA) followed by post hoc intergroup comparisons with Holm-
Sidak’s multiple comparisons test. 
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Highlights 
 
 Chronic hyperphenylalaninemia in C57Bl6-Pahenu2/enu2, a model of human 
phenylketonuria, is associated with brain dopamine and serotonin deficiencies 
with severe behavioral alterations and cognitive impairment. 
 Phenylalanine reducing treatments, including dietary phenylalanine restriction or 
liver directed gene therapy, initiated during adulthood yielded increased brain 
monoamine neurotransmitter content and improved nesting behavior, but no 
change in cognitive impairments. 
 Phenylalanine-mediated competitive inhibition of tyrosine hydroxylase and 
tryptophan hydroxylase 2 activities appears to the predominant mechanism 
causing CNS monoamine neurotransmitter deficiency in hyperphenylalaninemic 
mice. 
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